摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole | 414882-56-7

中文名称
——
中文别名
——
英文名称
3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole
英文别名
3-[[4-(2-ethoxyphenyl)piperazin-1-yl]methyl]-1H-indole
3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole化学式
CAS
414882-56-7
化学式
C21H25N3O
mdl
——
分子量
335.449
InChiKey
PFALMGBZVKYODL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    31.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    吲哚聚合甲醛1-(2-乙氧基苯基)哌嗪溶剂黄146 为溶剂, 反应 1.0h, 以66%的产率得到3-{[4-(2-ethoxyphenyl)-piperazin-1-yl]methyl}-1H-indole
    参考文献:
    名称:
    通过交互式SAR研究发现强效和选择性D4配体
    摘要:
    合成了一系列噻吩甲基苯基哌嗪并测试了其对五种多巴胺能受体亚型的亲和力。化合物5f对D4受体显示出超过1000倍的选择性。类似物5e显示出对K i 3.9 nM的D4受体的最高亲和力。采用了交互式SAR方法,导致化合物14a的K i(D4)低至0.03 nM。分子对接研究表明,有潜力首先报道D4独特残基Arg-186与配体芳烃部分之间的芳烃阳离子相互作用,这说明在化合物结构的这一区域具有强的负静电势的重要性。
    DOI:
    10.1016/j.bmcl.2013.07.033
点击查看最新优质反应信息

文献信息

  • 5HT7 receptor ligands and compositions comprising the same
    申请人:Laboratorios Del. Dr. Esteve, S.A.
    公开号:EP2149373A1
    公开(公告)日:2010-02-03
    The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.
    本发明涉及具有药理活性的化合物,特别是作为5-HT7受体激动剂,通过使用药效团和描述符的配置文件筛选识别,以及包含它们的药物组合物。这些化合物在治疗中特别有用,特别是用于治疗和/或预防涉及5-HT7的疾病,如中枢神经系统紊乱。
  • Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter
    申请人:Laboratorios Del. Dr. Esteve, S.A.
    公开号:EP2151777A1
    公开(公告)日:2010-02-10
    The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor; to a method for identifying them as 5-HT7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.
    本发明涉及对5-HT7受体具有药理活性的化合物;涉及通过使用药效谱和描述符特征过滤器将它们鉴定为5-HT7配体,特别是激动剂的方法;涉及包含它们的药物组合物;涉及它们在治疗中的用途,特别是用于治疗和预防5-HT7参与的疾病,如中枢神经系统疾病。
  • METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER
    申请人:Pascual-Ramon Rosalia
    公开号:US20110124657A1
    公开(公告)日:2011-05-26
    The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor; to a method for identifying them as 5-HT 7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
  • 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME
    申请人:Pascual-Ramon Rosalia
    公开号:US20110183991A1
    公开(公告)日:2011-07-28
    The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
查看更多